阿斯利康携四项重要研究首发数据亮相欧洲肿瘤内科学会（ESMO）年会，进一步彰显重新定义癌症治疗的雄心

2025-10-14 21:00 来源:阿斯利康

阿斯利康

    DESTINY-Breast11与DESTINY-Breast05两项研究入选主席研讨会（Presidential Symposium），凸显德曲妥珠单抗在治疗HER2阳性早期乳腺癌中的潜在价值

    TROPION-Breast02研究数据将展示德达博妥单抗在转移性三阴性乳腺癌这一最具侵袭性的乳腺癌分型中的治疗潜力

    POTOMAC研究的无病生存期数据与MATTERHORN研究的生存期数据将展示度伐利尤单抗在早期膀胱癌与胃癌治疗中的获益

    上海2025年10月14日 /美通社/ -- 阿斯利康将于2025年10月17日至21日召开的欧洲肿瘤内科学会（ESMO）年会上，凭借⾏业领先的多样化产品与管线布局的全新研究数据，进一步彰显其重新定义癌症治疗格局的雄心壮志。


    本次大会上，阿斯利康将公布逾95项摘要，涵盖9款已获得批准药物及9款潜在新药，包括2项入选重要主席研讨会（Presidential Symposium）的摘要以及26项口头报告。

    其中主要亮点包括：

    • DESTINY-Breast11：评估德曲妥珠单抗序贯THP方案（紫杉醇、曲妥珠单抗及帕妥珠单抗）用于高风险HER2阳性早期乳腺癌新辅助治疗的III期临床研究（主席研讨会1，摘要#291O）。
    • DESTINY-Breast05：评估德曲妥珠单抗用于HER2阳性早期乳腺癌（新辅助治疗后存在残留浸润病灶并具有高复发风险）的III期临床研究（主席研讨会1，摘要#LBA1）。
    • TROPION-Breast02：评估德达博妥单抗用于一线治疗无法接受免疫治疗的局部复发性不可手术或转移性三阴性乳腺癌（TNBC）患者的III期临床研究（优选论文摘要#LBA21）。
    • POTOMAC：评估度伐利尤单抗联合卡介苗（BCG）诱导与维持治疗，用于高危非肌层浸润性膀胱癌（NMIBC）患者的III期临床研究（优选论文摘要#LBA108）。
    • MATTERHORN：公布III期临床研究的最终总生存期（OS）结果，评估度伐利尤单抗联合FLOT化疗作为可切除的早期和局部晚期的胃和胃⻝管结合部腺癌（GEJ）患者围手术期治疗中的临床获益（优选论文摘要#LBA81）。

    阿斯利康全球执行副总裁、全球肿瘤研发负责人高书璨（Susan Galbraith）表示："我们正加速推进多元创新疗法管线，以变革乳腺癌患者的治疗格局。在本届ESMO大会上，我们将公布TROPION-Breast02、DESTINY-Breast11和DESTINY-Breast05研究的数据和重要进展。同时，我们也将展示新一代潜在抗肿瘤新药的数据，包括saruparib联合新型激素疗法用于前列腺癌领域，靶向叶酸受体的抗体偶联药物torvu-sam用于卵巢癌领域，以及rilvegostomig用于在非小细胞肺癌领域。"

    阿斯利康全球执行副总裁，肿瘤业务负责人Dave Fredrickson表示："我们业界领先的肿瘤产品组合在本次ESMO持续展现强劲势头，首次公布了四项关键研究的数据。其中，不仅有德曲妥珠单抗和德达博妥单抗在乳腺癌领域的重大进展，度伐利尤单抗的POTOMAC试验结果也证明了免疫疗法为早期膀胱癌治疗带来的益处，进而阐释我们的策略——将前沿治疗引入癌症早期这一患者最能够获益的阶段。"

    其他亮点包括：

    • FONTANA：评估靶向叶酸受体α（FRα）的抗体药物偶联物AZD5335用于铂耐药复发性卵巢癌患者的I/IIa期首次人体临床试验（简短口头报告摘要#1065MO）。
    • PETRANHA：评估saruparib联合雄激素受体通路抑制剂用于治疗转移性前列腺癌患者的I/II期临床研究（简短口头报告摘要#2384MO）。
    • ARTEMIDE-01：评估rilvegostomig用于检查点抑制剂初治的转移性非小细胞肺癌（NSCLC）患者的I/II期临床研究（简短口头报告摘要#1853MO）。
    • FLAURA2：在奥希替尼合化疗治疗晚期EGFR突变NSCLC患者的FLAURA2 III期临床研究中存在不良预后因素患者的探索性OS分析（优选论文摘要#LBA77）。
    • CAPItello-281：卡匹色替联合阿比特龙和雄激素剥夺疗法（ADT）用于PTEN缺陷的新发转移性激素敏感性前列腺癌（mHSPC）的III期临床研究（优选论文摘要#2383O）。
    • TROPION-PanTumor03：评估德达博妥单抗联合rilvegostomig治疗局晚期或转移性尿路上皮癌（a/mUC）患者的疗效： II期TROPION-PanTumor03研究结果结果（简短口头报告摘要 #3072MO）
    • BEGONIA：德达博妥单抗联合度伐利尤单抗用于既往未经治疗的不可切除、局部晚期或转移性三阴性乳腺癌（TNBC）患者的BEGONIA Ib/II期试验最终结果（口头报告摘要#555MO）。

    阿斯利康与第⼀三共联合开发和商业化德曲妥珠单抗与德达博妥单抗；与默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）联合开发和商业化奥拉帕利；与和黄医药合作开发和商业化赛沃替尼。Rilvegostomig是一种靶向PD-1和TIGIT的双特异性抗体，其中TIGIT部分源自Compugen公司临床阶段的抗TIGIT抗体COM902。

    阿斯利康在2025年ESMO年会期间的重要演讲[1]

    主要作者

    摘要标题

    报告详情(CEST)

    抗体偶联药物

    Harbeck, N

    DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan
    alone (T-DXd) or followed by paclitaxel + trastuzumab +
    pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+
    early breast cancer (eBC)

    Abstract #291O

    Presidential 1

    18 October 2025

    4:30 PM

    Geyer, C

    Trastuzumab deruxtecan (T-DXd) vs trastuzumab
    emtansine (T-DM1) in patients (pts) with high-risk human
    epidermal growth factor receptor 2–positive (HER2+)
    primary breast cancer (BC) with residual invasive disease
    after neoadjuvant therapy (tx): Interim analysis of
    DESTINY-Breast05

    Abstract #LBA1

    Presidential 1

    18 October 2025

    4:52 PM

    Dent, R.

    First-line (1L) datopotamab deruxtecan (Dato-DXd) vs
    chemotherapy in patients with locally recurrent inoperable
    or metastatic triple-negative breast cancer (mTNBC) for
    whom immunotherapy was not an option: Primary results
    from the randomised, phase 3 TROPION-Breast02 trial

    Abstract #LBA21

    Proffered Paper Session

    19 October 2025

    9:25 AM

    Loibl, S

    Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane
    + trastuzumab + pertuzumab (THP) for patients with
    HER2+ advanced/metastatic breast cancer: additional
    analysis of DESTINY-Breast09 in key subgroups of interest

    Abstract #LBA18

    Proffered Paper Session

    19 October 2025

    8:30 AM

    Rha, SY

    Datopotamab deruxtecan (Dato-DXd) + rilvegostomig
    (rilve) in patients (pts) with locally advanced or metastatic
    urothelial cancer (a/mUC): Results from the phase 2
    TROPION-PanTumor03 study

    Abstract #3072MO

    Mini Oral Session

    17 October 2025

    4:10 PM

    Oaknin, A

    First-in-human study of AZD5335, a folate receptor α
    (FRα)-targeted antibody-drug conjugate, in patients with
    platinum-resistant recurrent ovarian cancer

    Abstract #1065MO

    Mini Oral Session

    19 October 2025

    10:53 AM

    Schmid, P

    Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as
    first-line (1L) treatment (tx) for unresectable locally
    advanced/metastatic triple-negative breast cancer
    (a/mTNBC): Final results from the phase 1b/2 BEGONIA
    study

    Abstract #555MO

    Mini Oral Session

    20 October 2025

    10:50 AM

    Raghav, K

    Trastuzumab deruxtecan (T DXd) in patients (pts) with
    HER2-positive (HER2+) metastatic colorectal cancer
    (mCRC): Final analysis of DESTINY-CRC02, a
    randomized, phase 2 trial

    Abstract #737P

    Poster Session

    Peng, Z

    Trastuzumab deruxtecan (T-DXd) in patients (pts) with
    HER2+ gastric cancer (GC) or gastroesophageal junction
    adenocarcinoma (GEJA) who received prior anti-HER2
    treatment (Tx) other than / in addition to trastuzumab in
    DESTINY-Gastric06 (DG-06)

    Abstract #2105P

    Poster Session

    Shen, L

    Risk of hepatitis B virus reactivation (HBVr) in patients
    (pts) with past or resolved HBV or inactive chronic HBV
    infection treated with trastuzumab deruxtecan (T-DXd) in
    the DESTINY-Gastric06 (DG-06) trial

    Abstract #2175P

    Poster Session

    Pietrantonio, F

    Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM)
    plus paclitaxel (PTX) in second-line (2L) treatment of
    patients (pts) with HER2+ unresectable/metastatic gastric
    cancer (GC)/gastroesophageal junction adenocarcinoma
    (GEJA): Additional data from DESTINY-Gastric04 (DG-04)

    Abstract #2099P

    Poster Session

    Makker, V

    Trastuzumab deruxtecan (T-DXd) for pretreated patients
    (pts) with HER2-expressing solid tumors: DESTINY-
    PanTumor02 (DP-02) Part 1 final analysis

    Abstract #957P

    Poster Session

    Lee, J-Y

    Trastuzumab deruxtecan (T-DXd) in pretreated patients
    (pts) with HER2-expressing solid tumors: exploratory
    biomarker analysis of DESTINY-PanTumor02 (DP-02) Part
    1

    Abstract #145P

    Poster Session

    免疫肿瘤学

    Tabernero, J

    MATTERHORN Phase III trial of Imfinzi (durvalumab)
    perioperative Imfinzi (durvalumab) plus FLOT
    chemotherapy in patients with resectable, early-stage and
    locally advanced gastric and gastroesophageal junction
    (GEJ) cancers

    Abstract #LBA81

    Proffered Paper Session

    17 October 2025

    2:00 PM

    De Santis, M

    Durvalumab (D) in Combination with Bacillus Calmette-
    Guérin (BCG) for BCG-naïve, High-risk Non-muscle-
    invasive Bladder Cancer (NMIBC): Results from the Phase
    3, Open-label, Randomised POTOMAC Trial

    Abstract #LBA108

    Proffered Paper Session

    17 October 2025

    2:10 PM

    Larkin, J

    First results from RAMPART: An international phase 3
    randomised-controlled trial of adjuvant durvalumab
    monotherapy or combined with tremelimumab for resected
    primary renal cell carcinoma (RCC) led by MRC CTU at
    UCL

    Abstract #LBA93

    Proffered Paper Session

    18 October 2025

    9:20 AM

    Aghajanian, C

    Durvalumab + paclitaxel/carboplatin + bevacizumab
    followed by durvalumab, bevacizumab + olaparib
    maintenance in patients with newly diagnosed non-tBRCA-
    mutated advanced ovarian cancer: final overall survival
    from DUO-O/ENGOT-ov46/GOG-3025

    Abstract #LBA44

    Mini Oral Session

    19 October 2025

    11:31 AM

    Goss, G

    CCTG BR.31: Adjuvant durvalumab (D) in resected non-
    small-cell lung cancer (NSCLC): final overall survival (OS)
    and minimal residual disease (MRD) analyses

    Abstract #LBA68

    Mini Oral Session

    20 October 2025

    3:20 PM

    Heymach, J

    Association of radiomic features ± on-treatment ctDNA
    detection with treatment outcomes in patients with
    resectable NSCLC: exploratory analyses from AEGEAN

    Abstract #LBA70

    Mini Oral Session

    20 October 2025

    3:50 PM

    Wermke, M

    Tarlatamab with first-line chemoimmunotherapy for
    extensive stage small cell lung cancer (ES-SCLC):
    DeLLphi-303 study

    Abstract #2757O

    Proffered Paper Session

    18 October 2025

    8:30 AM

    Loibl, S

    Durvalumab in Combination with Neoadjuvant
    Chemotherapy in Early Triple-Negative Breast Cancer
    (TNBC) – Long-term Analysis from the GeparNuevo Trial

    Abstract #292MO

    Mini Oral Session

    19 October 2025

    10:15 AM

    Van der Heijden, M

    Health-related quality of life (HRQoL) from the NIAGARA
    trial of perioperative durvalumab (D) plus neoadjuvant
    chemotherapy (NAC) in muscle-invasive bladder cancer
    (MIBC)

    Abstract #3069MO

    Mini Oral Session

    17 October 2025

    4:00 PM

    Sangro, B

    Pooled efficacy and safety outcomes with tremelimumab
    plus durvalumab in participants (pts) with unresectable
    hepatocellular carcinoma (uHCC) from the combined
    China extension and global cohorts in the Phase 3
    HIMALAYA study

    Abstract #1494P

    Poster Session

    Westin, S

    Durvalumab plus carboplatin/paclitaxel followed by
    durvalumab for endometrial cancer: Tumour mutational
    burden-high subpopulation efficacy analyses from the
    DUO-E trial

    Abstract #1117P

    Poster Session

    Leal, TA

    Global quantitative assessment of multidisciplinary team
    (MDT) care in early-stage NSCLC

    Abstract #1794P

    Poster Session

    Reck, M

    Neoadjuvant durvalumab (D) + chemotherapy (CT)
    followed by either surgery (Sx) and adjuvant D or CRT and
    consolidation D in patients (pts) with resectable or
    borderline resectable stage IIB–IIIB NSCLC: interim
    analysis (IA) of the phase 2 MDT-BRIDGE study

    Abstract #LBA65

    Proffered Paper Session

    18 October 2025

    9:15 AM

    Maruki, Y

    CELEBRATE Study (JCOG2107E): A Multicenter, Open-
    label, Phase III Trial of Etoposide, Carboplatin, and
    Durvalumab in First-line Treatment of Unresectable or
    Recurrent Digestive NEC

    Abstract #1734TiP

    Poster Session

    Oudard, S

    A phase IIIb, open-label, single-arm, global study of
    perioperative durvalumab (D) with neoadjuvant dose-
    dense methotrexate, vinblastine, doxorubicin, and cisplatin
    (ddMVAC) or gemcitabine/cisplatin (gem/cis) in patients
    with muscle-invasive bladder cancer (MIBC) (NIAGARA-2)

    Abstract #3133eTiP

    ePoster Session

    双特异性抗体

    Chul Cho, B

    Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT
    Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve
    Metastatic Non-Small-Cell Lung Cancer (mNSCLC):
    ARTEMIDE-01

    Abstract #1853MO

    Mini Oral Session

    20 October 2025

    10:25 AM

    Slomovitz, BM

    A randomized Phase 3 study of first-line (1L) trastuzumab
    deruxtecan (T-DXd) with rilvegostomig or pembrolizumab
    in patients with HER2-expressing, mismatch repair-
    proficient (pMMR), primary advanced or recurrent
    endometrial cancer (EC): DESTINY-Endometrial01/GOG-
    3098/ENGOT-EN24

    Abstract #1223TiP

    Poster Session

    Naidoo, J

    ARTEMIDE-Lung04: A Phase 3, randomised, double-blind,
    global study of rilvegostomig or pembrolizumab
    monotherapy as first-line (1L) treatment for patients with
    metastatic non-small cell lung cancer (mNSCLC) and

    programmed cell death ligand-1 (PD-L1) expression ≥50%

    Abstract #2025TiP

    Poster Session

    肿瘤驱动因子和耐药性

    Jänne, PA

    FLAURA2: exploratory overall survival (OS) analysis in
    patients (pts) with poor prognostic factors treated with
    osimertinib (osi) ± platinum-pemetrexed chemotherapy
    (CTx) as first-line (1L) treatment for EGFR-mutated
    (EGFRm) advanced NSCLC

    Abstract #LBA77

    Proffered Paper Session

    17 October 2025

    4:56 PM

    Mayer, E

    Patient-reported outcomes (PROs) from the SERENA-6
    trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i)
    for emergent ESR1m during first-line (1L) endocrine-based
    therapy and ahead of disease progression in patients (pts)
    with HR+/HER2- advanced breast cancer (ABC)

    Abstract #486MO

    Mini Oral Session

    20 October 2025

    10:25 AM

    Arriola, E

    Molecular residual disease (MRD) analysis from the
    LAURA study of osimertinib (osi) in unresectable (UR)
    stage III EGFR-mutated (EGFRm) NSCLC

    Abstract #1817MO

    Mini Oral Session

    20 October 2025

    2:55 PM

    Park, YH

    Visual symptom questionnaire results from SERENA-6, a
    Phase 3 study of switch to camizestrant (CAMI) + CDK4/6
    inhibitor (CDK4/6i) at emergence of ESR1m during first-
    line (1L) therapy for patients (pts) with HR+/HER2-
    advanced breast cancer (ABC)

    Abstract #528P

    Poster Session

    Chu, Q

    SAVANNAH: Safety and tolerability of osimertinib (osi) +
    savolitinib (savo) in EGFRm advanced NSCLC with MET
    overexpression and/or amplification (OverExp/Amp)
    following disease progression on osi

    Abstract #1955P

    Poster Session

    Rotow, J

    MET testing and treatment (tx) sequencing after
    progression on first line (1L) osimertinib (osi) in patients
    (pts) with EGFRm advanced NSCLC and acquired MET
    overexpression and/or amplification (OverExp/Amp):
    Interim analysis of a global real world (rw) study

    Abstract #1967P

    Poster Session

    Yu, Y

    ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo)
    plus osimertinib (osi) versus chemotherapy (chemo) in
    MET-amplified (METamp) advanced NSCLC after disease
    progression (PD) on EGFR tyrosine kinase inhibitor (TKI)

    Abstract #1954P

    Poster Session

    DNA损伤应答

    Azad, AA

    First interim efficacy analysis of the Phase 1/2 PETRANHA
    trial of saruparib + androgen receptor pathway inhibitors
    (ARPI) in patients (pts) with metastatic prostate cancer
    (mPC)

    Abstract #2384MO

    Mini Oral Session

    17 October 2025

    2:35 PM

    Fizazi, K

    A Phase 3 study of capivasertib (capi) + abiraterone (abi)
    vs placebo (pbo) + abi in patients (pts) with PTEN deficient
    de novo metastatic hormone-sensitive prostate cancer
    (mHSPC): CAPItello-281

    Abstract #2383O

    Proffered Paper Session

    19 October 2025

    11:19 AM

    Rugo, HS

    Capivasertib with fulvestrant as first- and second-line
    endocrine therapy in PIK3CA/AKT1/PTEN-altered
    hormone receptor-positive advanced breast cancer:
    Subgroup analysis from the Phase 3 CAPItello-291 trial

    Abstract #526P

    Poster Session

    Gao, Q

    Final overall survival (OS) analysis of L-MOCA: olaparib
    maintenance monotherapy in patients (pts) with platinum-
    sensitive relapsed ovarian cancer (PSR OC)

    Abstract #1090P

    Poster Session

    AI驱动的临床试验

    Gonuguntla, HK

    Real-World Validation of AI-defined Lung Nodule
    Malignancy Score (qXR-LNMS) in Predicting Risk of Lung
    Cancer: Interim results from Phase 2

    Abstract #2978P

    Poster Session

    [1]阿斯利康在2025年ESMO年会将公布逾90个摘要，涵盖其产品和管线中的分子药物

    关于阿斯利康肿瘤领域的研究

    阿斯利康正引领着肿瘤领域的⼀场革命，致力提供多元化的肿瘤治疗方案，以科学探索肿瘤领域的复杂性，发现、研发并向患者提供改变生命的药物。

    阿斯利康专注于最具挑战性的肿瘤疾病，通过持续不断的创新，阿斯利康已经建立了行业领先的多元化的 产品组合和管线，持续推动医疗实践变⾰，改变患者体验。

    阿斯利康以期重新定义癌症治疗并在未来攻克癌症。

    关于阿斯利康

    阿斯利康（LSE/STO/Nasdaq: AZN）是⼀家科学至上的全球生物制药企业，专注于研发、生产及营销处方类药品，重点关注肿瘤、罕见病以及包括心血管肾脏及代谢、呼吸及免疫在内的生物制药等领域。阿斯利康全球总部位于英国剑桥，业务遍布超过125个国家，创新药物惠及全球数百万患者。更多信息，请访问www.astrazeneca.com。

    关于阿斯利康中国

    阿斯利康自1993年进入中国以来，专注中国患者需求最迫切的治疗领域，包括肿瘤、心血管、肾脏、代谢、呼吸、消化、罕见病、疫苗抗体及自体免疫等，已将40多款创新药物带到中国。阿斯利康中国总部位于上海，并在上海和北京设立全球战略研发中心，在北京、广州、杭州、成都、青岛设立区域总部，在无锡、泰州、青岛建立全球生产供应基地，向全球70多个市场输送优质创新药品。

    声明：本文研究中涉及的多种药品用法尚未在中国获批适应症，阿斯利康不推荐任何未被批准的药品使用。

（免责声明：本文来源于网络，仅做公益分享，版权归原作者所有，若有版权问题请告知删除！本文不代表本网站的观点和立场。）